United Kingdom · Question · Written question
UIN 94868
Tixagevimab/cilgavimab
Original
Introduced
23 November 2022
Last action
20 December 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
20 December 2022
Summary
To ask the Secretary of State for Health and Social Care, if he will publish a list of all available world-wide source material on the effectiveness of Evusheld and within that list, to identify which source material, if any, were excluded by Rapid C-19 w
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
23 November 2022
Written question
To ask the Secretary of State for Health and Social Care, if he will publish a list of all available world-wide source material on the effectiveness of Evusheld and within that list, to identify which source material, if any, were excluded by Rapid C-19 w
Source: Commons
20 December 2022
Answer
An exhaustive list of all available world-wide sources is not held centrally. RAPID C-19 has considered the evidence base for the effectiveness for Evusheld, including through monitoring the emerging data such clinical trials, in vitro analysis and observ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-11-23/94868
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1544944
- uk · wq-1544944 · source updated 20 December 2022